Peroxisome proliferator-activated receptor-γ is a potent target for prevention and treatment in human prostate and testicular cancer

PPAR Research

Volumn , Issue , 2008, Pages

  Matsuyama, Masahide ^a   Yoshimura, Rikio ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ADIPOCYTE; ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL VIABILITY; FLOW CYTOMETRY; GROWTH DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS CANCER;

EID: 41149141789     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/249849     Document Type: Article

References (31)

1. W. K. Oh P. W. Kantoff Management of hormone refractory prostate cancer: current standards and future prospects. The Journal of Urology 160 4 1998 1220 1229
2. S. Bosari A. K. C. Lee R. A. DeLellis B. D. Wiley G. J. Heatley M. L. Silverman Microvessel quantitation and prognosis in invasive breast carcinoma. Human Pathology 23 7 1992 755 761
3. G. Chinetti S. Griglio M. Antonucci Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. Journal of Biological Chemistry 273 40 1998 25573 25580
4. B. M. Spiegelman bruce_spiegelman@dfci.harvard.edu PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 4 1998 507 514
5. E. Mueller P. Sarraf P. Tontonoz Terminal differentiation of human breast cancer through PPARγ Molecular Cell 1 3 1998 465 470
6. P. Sarraf E. Mueller D. Jones Differentiation and reversal of malignant changes in colon cancer through PPARγ Nature Medicine 4 9 1998 1046 1052
7. Y. Tsubouchi H. Sano hsano@koto.kpu-m.ac.jp Y. Kawahito Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochemical and Biophysical Research Communications 270 2 2000 400 405
8. N. Takahashi T. Okumura okumurat@asahikawa-med.ac.jp W. Motomura Y. Fujimoto I. Kawabata Y. Kohgo Activation of PPAR inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Letters 455 1-2 1999 135 139
9. S. Altiok M. Xu B. M. Spiegelman BruceSpiegelman@dfci.harvard.edu PPARγ induces cell cycle withdrawal: inhibition of E2f/DP DNA-binding activity via down-regulation of PP2A. Genes & Development 11 15 1997 1987 1998
10. D. Bishop-Bailey T. Hla hla@sun.uchc.edu Endothelial cell apoptosis induced by the peroxisome proliferator- activated receptor (PPAR) ligand 15-deoxy-δ12,14-prostaglandin J 2. Journal of Biological Chemistry 274 24 1999 17042 17048
11. K.-I. Inoue Y. Kawahito Y. Tsubouchi Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists. Biochemical and Biophysical Research Communications 287 3 2001 727 732
12. R. Yoshimura jasmin@med.osaka-cu.ac.jp M. Matsuyama Y. Segawa Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. International Journal of Cancer 104 5 2003 597 602
13. Y. Segawa R. Yoshimura T. Hase Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. The Prostate 51 2 2002 108 116
14. T. Hase R. Yoshimura M. Mitsuhashi Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists. Urology 60 3 2002 542 547
15. R. Yoshimura M. Matsuyama T. Hase The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. International Journal Of Molecular Medicine 12 2003 6 861 865
16. D. Paltoo paltoodi@mail.nih.gov K. Woodson P. Taylor D. Albanes J. Virtamo J. Tangrea Pro12Ala polymorphism in the peroxisome proliferator- activated receptor-gamma (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Letters 191 1 2003 67 74
17. V. Subbarayan A. L. Sabichi J. Kim Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiology Biomarkers & Prevention 13 11 2004 1710 1716
18. R. Butler S. H. Mitchell D. J. Tindall C. Y. F. Young youngc@mayo.edu Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-Deoxy-Δ12,14-prostaglandin J 2. Cell Growth & Differentiation 11 1 2000 49 61
19. D. Auboeuf J. Rieusset L. Fajas Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46 8 1997 1319 1327
20. H. Sano K. Engleka P. Mathern Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. The Journal of Clinical Investigation 91 2 1993 553 565
21. D. A. Kujubu S. T. Reddy B. S. Fletcher H. R. Herschman Expression of the protein product of the prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3 cells. Journal of Biological Chemistry 268 8 1993 5425 5430
22. S. M. Fitzgerald S. Flinn Evaluating research studies using the analysis of variance (ANOVA): issues and interpretations. Journal of Hand Therapy 13 1 2000 56 60
23. O. Braissant F. Foufelle C. Scotto M. Dauça W. Wahli Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137 1 1996 354 366
24. C. Dreyer G. Krey H. Keller F. Givel G. Helftenbein W. Wahli Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 5 1992 879 887
25. S. A. Kliewer K. Umesono D. J. Noonan R. A. Heyman R. M. Evans Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 6389 1992 771 774
26. S. A. Kliewer B. M. Forman B. Blumberg Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 91 15 1994 7355 7359
27. J. A. Keelan j.keelan@auckland.ac.nz T. A. Sato K. W. Marvin J. Lander R. S. Gilmour M. D. Mitchell 15-Deoxy-δ12,14-prostaglandin J 2 a ligand for peroxisome proliferator-activated receptor-γ, induces apoptosis in JEG3 choriocarcinoma cells. Biochemical and Biophysical Research Communications 262 3 1999 579 585
28. X. Xin S. Yang J. Kowalski M. E. Gerritsen meg@gene.com Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry 274 13 1999 9116 9121
29. T. Boehm J. Folkman T. Browder M. S. O'Reilly Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 6658 1997 404 407
30. M. S. O'Reilly T. Boehm Y. Shing Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 2 1997 277 285
31. J. Drevs I. Hofmann H. Hugenschmidt Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Research 60 17 2000 4819 4824